News|Articles|November 17, 2026

FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica

Listen
0:00 / 0:00

Key Takeaways

  • Secukinumab expands PMR steroid-sparing strategies beyond IL-6R blockade, addressing frequent relapse during tapering and reducing long-term corticosteroid toxicities such as osteoporosis and diabetes.
  • REPLENISH randomized 381 recently relapsed patients to secukinumab 300 mg, 150 mg, or placebo with a 24-week prednisone taper; primary endpoint required sustained remission from weeks 12–52.
SHOW MORE

The FDA approved secukinumab for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering, supported by improved sustained remission and reduced steroid exposure in REPLENISH.

The FDA approved secukinumab (Cosentyx; Novartis) 150 mg for adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering. Announced in a November 17, 2026, global release, the decision makes secukinumab the first FDA-approved biologic targeting interleukin-17 (IL-17) for PMR.¹

The approval adds a treatment option for patients whose disease remains difficult to control as steroid doses decrease. In the phase 3 REPLENISH trial (NCT05767034), approximately twice as many patients receiving secukinumab 150 mg achieved sustained remission at week 52 compared with placebo, with both groups following a 24-week steroid taper.¹

Expanding Options Beyond Prolonged Corticosteroid Treatment

PMR primarily affects adults aged 50 years and older and causes pain and stiffness around the shoulders and hips. Symptoms can interfere with dressing and getting out of bed, making disease control central to maintaining daily function. Corticosteroids remain standard treatment, but relapse during tapering can prolong exposure and complicate care.¹

Up to 40% of patients experience relapse within the first year, according to Novartis. Extended corticosteroid use carries risks that include osteoporosis and diabetes, creating a need for therapies that maintain remission while reducing steroid requirements.¹

Secukinumab selectively inhibits IL-17A, adding a different mechanism to the PMR treatment landscape. Sarilumab (Kevzara; Sanofi and Regeneron), an IL-6 receptor antagonist, is already FDA approved for adults with an inadequate corticosteroid response or intolerance to tapering. Secukinumab’s distinction is its IL-17 target.¹˒²

REPLENISH Demonstrates Sustained Remission and Steroid Sparing

REPLENISH was a randomized, double-blind, placebo-controlled trial enrolling 381 patients with recently relapsed PMR. Investigators assigned patients to secukinumab 300 mg, secukinumab 150 mg, or placebo for 52 weeks. Every group received prednisone tapered over 24 weeks. Results were published in the New England Journal of Medicine.³

The primary outcome assessed remission sustained from week 12 through week 52, without PMR signs or symptoms or a new diagnosis of giant cell arteritis warranting escape or rescue treatment.³

In the FDA prescribing information, sustained remission occurred in 40.5% of patients receiving the approved 150-mg dose versus 20.5% receiving placebo. These findings represent an approximately 20-percentage-point absolute improvement.¹˒⁴

Mean adjusted annual cumulative glucocorticoid exposure was 1683.2 mg with secukinumab 150 mg compared with 2093.0 mg with placebo. The reduction supports a steroid-sparing effect alongside improved remission, addressing a practical concern for patients who require repeated treatment after relapse.³

Although REPLENISH evaluated both secukinumab doses, the approved PMR regimen uses 150 mg. Pharmacists should verify the indication when reviewing prescriptions because secukinumab dosing varies across its approved uses.⁴

Safety Findings Require Attention to Infection Risk

Serious adverse events occurred in 15.9% of patients receiving secukinumab 150 mg and 14.2% receiving placebo. Hypersensitivity reactions occurred in 14% versus 9%, respectively, and urinary tract infections occurred in 13% versus 7%. One patient in the 150-mg group experienced a serious urinary tract infection. A fatal case of cryptococcal meningitis was reported in a secukinumab-treated patient.¹˒³

These findings make infection assessment and patient education important components of treatment initiation. The prescribing information advises evaluating patients for tuberculosis before treatment and completing age-appropriate vaccinations. Live vaccines should be avoided during therapy.⁴

What Pharmacists Should Know About the PMR Regimen

For PMR, secukinumab is administered subcutaneously at 150 mg at weeks 0, 1, 2, 3, and 4, followed by every 4 weeks. Treatment begins with a tapering glucocorticoid course; secukinumab can continue alone after glucocorticoids are discontinued.⁴

Pharmacists can reinforce the transition from weekly loading doses to maintenance injections and help patients follow the prescribed steroid taper. Counseling should emphasize reporting infection symptoms promptly and seeking immediate medical attention for serious allergic reactions. The label also advises caution in patients with inflammatory bowel disease.⁴

For patients eligible for the new indication, the approval broadens the opportunity to sustain disease control while reducing cumulative corticosteroid exposure.¹˒³

REFERENCES
  1. Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR). News release. Novartis. November 17, 2026. Accessed November 17, 2026. https://www.novartis.com/news/media-releases/novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-people-polymyalgia-rheumatica-pmr
  2. Kevzara. Prescribing information. Sanofi-Aventis U.S. LLC. Accessed November 17, 2026. https://products.sanofi.us/kevzara/kevzara.pdf
  3. Stone JH, Buttgereit F, Saraux A, et al. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. N Engl J Med. 2026;395(7):637-647. doi:10.1056/NEJMoa2602567
  4. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corporation. Revised November 2026. Accessed November 17, 2026. cosentyx.pdf

Related to this article